"Superior Efficacy Compared to Tagrisso," Study Published in NEJM... Approval Expected in August
Leclaza Combination Therapy Study Published in NEJM, Raising Expectations for FDA Approval
A study demonstrating the superior efficacy of the combination therapy of Yuhan Corporation's non-small cell lung cancer (NSCLC) treatment, Leclaza (ingredient name: lazertinib), over the monotherapy…